Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of adjunctive metformin in newly diagnosed IDH-wildtype glioblastoma
2022-003595-16Phase 2Active
- Sponsor
- University of Milano-Bicocca
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of metformin in glioblastoma (GBM), sponsored by University of Milano-Bicocca. Primary endpoint: Progression-free survival at 6 months. Started Jan 2023; status: active.
02
Drugs
metformin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2022-003595-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003595-16.